Morgan Stanley Reiterates Overweight Rating on BioNTech (BNTX): "timing of announcement likely driving weakness in stock"
March 10, 2026 12:06 PM
Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $134.00 price target on BioNTech (NASDAQ: BNTX)The analyst commented, "BNTX ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
